FDA approves treatment for gastrointestinal stromal tumors

The US Food and Drug Administration (FDA) Monday approved the use of Stivarga (regorafenib) to treat certain advanced gastrointestinal stromal tumors (GISTs). The drug is already approved to treat colon and rectal cancer. The new approval is for GIST that cannot be removed by surgery or has spread to other parts of the body (metastasized) and is no longer responding to other drugs used to treat the disease. Read more here.